Locust Walk Acquisition Corp (LWAC) to Combine with eFFECTOR Therapeutics in $419M Deal

Locust Walk Acquisition Corp (LWAC) to Combine with eFFECTOR Therapeutics in $419M Deal

Locust Walk (NASDAQ:LWAC) has entered into a definitive agreement to combine with biopharmaceutical firm eFFECTOR at an enterprise value of $419 million. San Diego-based eFFECTOR has two clinical-stage and one preclinical drug candidates with potential use as cancer therapies. One has also received federal funding to analyze its effectiveness as a COVID-19 antiviral drug. The
Read More
To access this post, you must purchase a Monthly or Yearly SPACInsider Subscription, or log in if you're a member.